Anaesthetic-analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT.


Journal

Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 16 7 2019
pubmed: 16 7 2019
medline: 2 10 2020
Statut: ppublish

Résumé

Acute otitis media (AOM) is a common reason for primary care consultations and antibiotic prescribing in children. Options for improved pain control may influence antibiotic prescribing and consumption. The Children's Ear Pain Study (CEDAR) investigated whether or not providing anaesthetic-analgesic ear drops reduced antibiotic consumption in children with AOM. Secondary objectives included pain control and cost-effectiveness. A multicentre, randomised, parallel-group (two-group initially, then three-group) trial. Primary care practices in England and Wales. 1- to 10-year-old children presenting within 1 week of suspected AOM onset with ear pain during the preceding 24 hours and not requiring immediate antibiotics. Participating children were logged into the study and allocated using a remote randomisation service. Two-group trial - unblinded comparison of anaesthetic-analgesic ear drops versus usual care. Three-group trial - blinded comparison of anaesthetic-analgesic ear drops versus placebo ear drops and unblinded comparison with usual care. The primary outcome measure was parent-reported antibiotic use by the child over 8 days following enrolment. Secondary measures included ear pain at day 2 and NHS and societal costs over 8 days. Owing to a delay in provision of the placebo drops, the recruitment period was shortened and most participants were randomly allocated to the two-group study ( Estimated treatment effects are imprecise because the sample size target was not met. It is not clear if delayed prescriptions of an antibiotic were written prior to randomisation. Few children received placebo drops, which hindered the investigation of ear pain. This study suggests that reduced antibiotic use can be achieved in children with AOM by combining a no or delayed antibiotic prescribing strategy with anaesthetic-analgesic ear drops. Whether or not the active drops relieved ear pain was not established. The observed reduction in antibiotic consumption following the prescription of ear drops requires replication in a larger study. Future work should establish if the effect of ear drops is due to pain relief. Current Controlled Trials ISRCTN09599764. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Ear infections are common in children < 10 years of age, with 40% of these children suffering from an ear infection at least once per year. During the infection, germs multiply in the confined space of the middle ear, resulting in a build-up of pressure that pushes on and stretches the ear drum. This causes severe pain and distress to the child, which in turn leads to disrupted family life. Although there is world-class evidence showing that antibiotics do not help, and the National Institute for Health and Care Excellence advises against their use, > 85% of UK children with middle ear infections (acute otitis media) are prescribed an antibiotic, which is a higher percentage than for any other childhood infection. Antibiotics do not treat the child’s pain and, in most cases, they do not help to treat the infection (because many ear infections are caused by viruses that do not respond to antibiotics), but they can cause side effects (such as diarrhoea) and increase the problem of antibiotic resistance, which is a major public health concern. The Children’s Ear Pain Study (CEDAR) wanted to find out whether or not painkilling ear drops [benzocaine–phenazone otic solution (Auralgan

Sections du résumé

BACKGROUND
Acute otitis media (AOM) is a common reason for primary care consultations and antibiotic prescribing in children. Options for improved pain control may influence antibiotic prescribing and consumption.
OBJECTIVE
The Children's Ear Pain Study (CEDAR) investigated whether or not providing anaesthetic-analgesic ear drops reduced antibiotic consumption in children with AOM. Secondary objectives included pain control and cost-effectiveness.
DESIGN
A multicentre, randomised, parallel-group (two-group initially, then three-group) trial.
SETTING
Primary care practices in England and Wales.
PARTICIPANTS
1- to 10-year-old children presenting within 1 week of suspected AOM onset with ear pain during the preceding 24 hours and not requiring immediate antibiotics. Participating children were logged into the study and allocated using a remote randomisation service.
INTERVENTIONS
Two-group trial - unblinded comparison of anaesthetic-analgesic ear drops versus usual care. Three-group trial - blinded comparison of anaesthetic-analgesic ear drops versus placebo ear drops and unblinded comparison with usual care.
MAIN OUTCOME MEASURES
The primary outcome measure was parent-reported antibiotic use by the child over 8 days following enrolment. Secondary measures included ear pain at day 2 and NHS and societal costs over 8 days.
RESULTS
Owing to a delay in provision of the placebo drops, the recruitment period was shortened and most participants were randomly allocated to the two-group study (
LIMITATIONS
Estimated treatment effects are imprecise because the sample size target was not met. It is not clear if delayed prescriptions of an antibiotic were written prior to randomisation. Few children received placebo drops, which hindered the investigation of ear pain.
CONCLUSIONS
This study suggests that reduced antibiotic use can be achieved in children with AOM by combining a no or delayed antibiotic prescribing strategy with anaesthetic-analgesic ear drops. Whether or not the active drops relieved ear pain was not established.
FUTURE WORK
The observed reduction in antibiotic consumption following the prescription of ear drops requires replication in a larger study. Future work should establish if the effect of ear drops is due to pain relief.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN09599764.
FUNDING
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
Ear infections are common in children < 10 years of age, with 40% of these children suffering from an ear infection at least once per year. During the infection, germs multiply in the confined space of the middle ear, resulting in a build-up of pressure that pushes on and stretches the ear drum. This causes severe pain and distress to the child, which in turn leads to disrupted family life. Although there is world-class evidence showing that antibiotics do not help, and the National Institute for Health and Care Excellence advises against their use, > 85% of UK children with middle ear infections (acute otitis media) are prescribed an antibiotic, which is a higher percentage than for any other childhood infection. Antibiotics do not treat the child’s pain and, in most cases, they do not help to treat the infection (because many ear infections are caused by viruses that do not respond to antibiotics), but they can cause side effects (such as diarrhoea) and increase the problem of antibiotic resistance, which is a major public health concern. The Children’s Ear Pain Study (CEDAR) wanted to find out whether or not painkilling ear drops [benzocaine–phenazone otic solution (Auralgan

Autres résumés

Type: plain-language-summary (eng)
Ear infections are common in children < 10 years of age, with 40% of these children suffering from an ear infection at least once per year. During the infection, germs multiply in the confined space of the middle ear, resulting in a build-up of pressure that pushes on and stretches the ear drum. This causes severe pain and distress to the child, which in turn leads to disrupted family life. Although there is world-class evidence showing that antibiotics do not help, and the National Institute for Health and Care Excellence advises against their use, > 85% of UK children with middle ear infections (acute otitis media) are prescribed an antibiotic, which is a higher percentage than for any other childhood infection. Antibiotics do not treat the child’s pain and, in most cases, they do not help to treat the infection (because many ear infections are caused by viruses that do not respond to antibiotics), but they can cause side effects (such as diarrhoea) and increase the problem of antibiotic resistance, which is a major public health concern. The Children’s Ear Pain Study (CEDAR) wanted to find out whether or not painkilling ear drops [benzocaine–phenazone otic solution (Auralgan

Identifiants

pubmed: 31304912
doi: 10.3310/hta23340
pmc: PMC6661537
doi:

Substances chimiques

Analgesics 0
Anesthetics 0
Anti-Bacterial Agents 0

Banques de données

ISRCTN
['ISRCTN09599764']

Types de publication

Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-48

Subventions

Organisme : Department of Health
ID : 13/88/13
Pays : United Kingdom

Déclaration de conflit d'intérêts

Alastair D Hay and William Hollingworth are members of the Health Technology Assessment Clinical Trials Board. Chris Metcalfe is a member of a clinical trials unit in receipt of National Institute for Health Research (NIHR) support funding. Desmond Nunez is an author of a related Cochrane review protocol. Paul Little is the Director of the NIHR Programme Grants for Applied Research programme and a member of the NIHR Journals Library Board.

Auteurs

Alastair D Hay (AD)

Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Harriet Downing (H)

National Institute for Health Research Biomedical Research Centre, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Nick A Francis (NA)

Division of Population Medicine, Cardiff University, Cardiff, UK.

Grace J Young (GJ)

Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Clare Clement (C)

Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Sue D Harris (SD)

Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Aideen Ahern (A)

Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Behnaz Schofield (B)

Division of Population Medicine, Cardiff University, Cardiff, UK.

Tammy E Thomas (TE)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Jeremy Horwood (J)

Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.
Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Peter S Blair (PS)

Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

William Hollingworth (W)

Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Victoria Wilson (V)

Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Chris Metcalfe (C)

Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Peter Stoddart (P)

Bristol Royal Hospital for Children, Bristol, UK.

Desmond Nunez (D)

Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.

Mark D Lyttle (MD)

Bristol Royal Hospital for Children, Bristol, UK.

Paul Little (P)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Michael V Moore (MV)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH